No Data
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $17
Amicus Therapeutics: Strong Financial Performance and Growth Prospects Justify Buy Rating
Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript Summary
Needham Maintains Amicus Therapeutics(FOLD.US) With Hold Rating
Amicus Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Revenue Growth Guidance.
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
No Data
No Data